FDA rejects Alnylam’s heart disease treatment over insufficient data

Also: In a setback for Novo Nordisk, a U.S. judge dismissed its lawsuit accusing a pharmacy of selling versions of Wegovy and Ozempic

October 9, 2023 Check out STAT+

Sponsored By

Courtesy Boehringer Ingelheim STAT+ | A Q&A with the global head of Boehringer Ingelheim's innovation unit At an event in London last week, the German pharmaceutical firm Boehringer Ingelheim outlined the projects in its pipeline.  By Andrew Joseph STAT+ | Delfi launches its blood test to screen for lung cancer – and reveals challenges for liquid biopsies Delfi appears to be the first in the growing field to focus its blood diagnostic test on lung cancer, the leading cause of cancer death. By Matthew Herper STAT+ | Bristol 'take-under' of Mirati is not so great for biotech, but company's new cancer target has potential Despite the underwhelming deal, PRMT5, the genetic cancer target that Mirati has been pursuing, seems to have potential. By Adam Feuerstein Kristoffer Tripplaar/Sipa USA/AP STAT+ | FDA rejects Alnylam's heart disease treatment over insufficient data The company said it will no longer seek approval of its ATTR-CM drug, an intravenous medicine sold as Onpattro. By Damian Garde STAT+ | Venture capital firm General Catalyst wants to buy a health system Venture firm General Catalyst is creating a health-focused business spinout with plans to buy a small or medium-sized health system. By Mohana Ravindranath STAT+ | Inflammation gets its own research center, thanks to Chan Zuckerberg Initiative The research center, a collaboration of Northwestern, UChicago and the University of Illinois, will start by building a model of skin. By Elaine Chen LISELOTTE SABROE/AFP/Getty Images STAT+ | Judge dismisses Novo Nordisk lawsuit over compounded versions of Ozempic and Wegovy The drug maker accused several compounders of selling versions of its medicines that were never approved by the Food and Drug Administration. By Ed Silverman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser